| Master Investor Magazine
|
The share price of AIM-listed stem cell therapeutics specialist ReNeuron Group (LON:RENE) has risen by 8.03% to 146.92p (as of 15:35 BST) after it announced the publication of new research data. The data shows the possibility of using the company’s method to produce non-donor specific treatments for a number of possible issues.
Head of Research Dr. Randolph Corteling commented: “The data we are presenting at the ESGCT Annual Congress represent a significant advance in the use of cell re-programming to generate new allogeneic cell lines as potential therapeutic candidates. Importantly, the maintenance of the immortalisation technology within these new cell lines may allow for the scaled production of ‘off the shelf’ allogeneic stem cells, such as haematopoietic stem cells as a potential alternative approach to those cancer immunotherapies currently in development that rely on the use of the patient’s own T-cells“.